Description
Endo S Enzyme
| Catalog number: | B2019365 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 2,500 units |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Powder |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | RT |
| Keywords: | Endo S Enzyme |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Yin O, Xiong Y, Endo S, Yoshihara K, Garimella T, AbuTarif M, Wada R, LaCreta F. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors Clin Pharmacol Ther. 2021 May;109(5):1314-1325.
- Endo S, Matsunaga T, Nishinaka T. The Role of AKR1B10 in Physiology and Pathophysiology Metabolites. 2021 May 21;11(6):332.
- Endo S. G-substrate: the cerebellum and beyond Prog Mol Biol Transl Sci. 2012;106:381-416.
- Doki Y, Nakazawa Y, Sukegawa M, Petrova RS, Ishida Y, Endo S, Nagai N, Yamamoto N, Funakoshi-Tago M, Donaldson PJ. Piezo1 channel causes lens sclerosis via transglutaminase 2 activation Exp Eye Res. 2023 Dec;237:109719.
- Takai T, Nakamura A, Endo S. Role of PIR-B in autoimmune glomerulonephritis J Biomed Biotechnol. 2011;2011:275302.
- Nozawa A, Ozeki M, Yasue S, Endo S, Noguchi K, Kanayama T, Tomita H, Aoki Y, Ohnishi H. Characterization of kaposiform lymphangiomatosis tissue-derived cells Pediatr Blood Cancer. 2021 Oct;68(10):e29086.
- Shiota M, Endo S, Tsukahara S, Tanegashima T, Kobayashi S, Matsumoto T, Eto M. Importance of 3-hydroxysteroid dehydrogenases and their clinical use in prostate cancer Endocr Relat Cancer. 2024 May 20;31(7):e240023.
- Sato K, Ota N, Endo S, Nakata A, Yamashita H, Tatsunami R. Effect of Chloroquine on Doxorubicin-induced Apoptosis in A549 Cells Anticancer Res. 2022 Aug;42(8):4025-4035.
- Honda T, Seto K, Endo S, Takemoto A, Tanimoto K, Kobayashi M, Kitano M, Sakakibara R, Mitsumura T, Ishibashi H, Inazawa J, Tanaka T, Miyazaki Y, Okubo K. The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non-small cell lung cancer Cancer Med. 2023 Oct;12(19):19406-19413.
